Table I.
Patient characteristics and outcome by stage, immunophenotype, LDH, primary site and age.
| Variable | Number (%) | 5-year OS (%) (95% CI) | 5-year EFS (%)(95% CI) | |||
|---|---|---|---|---|---|---|
| Stage | ||||||
| I | 31 | (54) | 96% | (76%-99%) | 89% | (70%-96%) |
| II | 20 | (36) | 94% | (65%-99%) | 89% | (64%-97%) |
| p-value | 0.41 | 0.98 | ||||
| Immunophenotype | ||||||
| Pre-B | 42 | (75) | 94% | (79%-99%) | 90% | (74%-96%) |
| Pre-T | 8 | (16) | 100% | 100% | ||
| p-value | 0.46 | 0.39 | ||||
| LDH | ||||||
| </= ULN | 49 | (87) | 95% | (82%-99%) | 89% | (75%-95%) |
| > ULN | 7 | (13) | 100% | 100% | ||
| p-value | 0.53 | 0.39 | ||||
| Primary Site | ||||||
| Bone | 10 | (18) | 100% | 90% | (47%-99%) | |
| Head & Neck | 37 | (66) | 96% | (77%-99%) | 91% | (74%-97%) |
| Non-head & Neck | 7 | (13) | 83% | (27%-97%) | 83% | (27%-97%) |
| p-value | 0.48 | 0.85 | ||||
| Age | ||||||
| < 10 years | 35 | (63) | 94% | (77%-98%) | 91% | (75%-97%) |
| ≥ 10 years | 21 | (37) | 100% | 90% | (64%-97%) | |
| p-value | 0.95 | 0.77 | ||||